Group 1 - The company has two innovative drugs, Lai Ruitewei tablets and Angladiwei tablets, that have been approved for market launch [1] - Angladiwei tablets have been included in the 2025 version of the National Medical Insurance Catalog [1] - The Phase III clinical trials for Angladiwei granules for treating uncomplicated influenza A in children aged 2 to 11 and Angladiwei tablets for treating uncomplicated influenza A in adolescents aged 12 to 17 have successfully completed participant enrollment [1]

Financial Performance - The company's net profit for 2025 is expected to be between RMB 260 million and RMB 310 million, representing a year-on-year growth of 186.91% to 203.62% [1] - The net profit after deducting non-recurring gains and losses is projected to be between RMB 270 million and RMB 320 million, with a growth rate of 203.72% to 222.93% [1] Strategic Partnerships - A licensing agreement was signed with Qilu Pharmaceutical on January 16, 2026, for the production and commercialization of RAY1225 injection in China, with an upfront payment of RMB 200 million [3] - The total potential milestone payments from Qilu Pharmaceutical could reach RMB 800 million, in addition to a double-digit royalty on net sales [3] Innovation and R&D Pipeline - The company focuses on innovative drug development for metabolic diseases and respiratory diseases, with two innovative drugs already approved for market [6][7] - RAY1225 injection, a dual receptor agonist, is currently undergoing multiple Phase III clinical trials for obesity and type 2 diabetes, showing promising efficacy and safety [11][12] - The company is also developing ZSP1601 tablets for metabolic dysfunction-related fatty liver disease, which has shown significant results in clinical trials [6] Market Opportunities - The market for metabolic-associated fatty liver disease (MASH) is substantial, with no approved treatments currently available, indicating a significant unmet clinical need [14] - Obstructive sleep apnea (OSA) affects approximately 176 million people in China, with RAY1225 injection potentially offering a new treatment option for this condition [16][18] Clinical Trial Progress - RAY1225 injection has completed Phase II trials with positive results, and Phase III trials are ongoing for various indications, including obesity and type 2 diabetes [12][17] - The company is committed to advancing its clinical trials with high quality and speed, focusing on innovative solutions for metabolic diseases and respiratory conditions [13]

Core Viewpoint - Zhongsheng Pharmaceutical (002317) is expected to achieve a net profit attributable to shareholders of 260 million to 310 million yuan in 2025, representing a year-on-year growth of 186.91% to 203.62%, marking a turnaround from losses [1] Group 1: Financial Performance - The company anticipates a significant increase in net profit for 2025, with projections indicating a range of 260 million to 310 million yuan [1] - This expected profit growth represents a substantial improvement compared to the previous year, indicating a turnaround from losses [1] Group 2: Strategic Focus - Zhongsheng Pharmaceutical is concentrating resources on the research and development of innovative drugs in the fields of metabolic diseases and respiratory diseases [1] - The company has successfully launched two innovative drugs, Lai Ru Te Wei tablets and Ang La Di Wei tablets, which are expected to be key growth drivers for future performance [1]

Company Performance - The company expects a net profit attributable to shareholders of 260 million to 310 million yuan for 2025, marking a turnaround from a loss in the previous year [1] - Basic earnings per share are projected to be between 0.31 yuan and 0.37 yuan, compared to a loss of 0.36 yuan per share in the same period last year [1] Strategic Focus - The performance change is primarily attributed to the company's strategic positioning of "traditional Chinese medicine as the foundation, innovation leading, and quality and efficiency being prioritized" [1] - The company is concentrating resources on the research and development of innovative drugs in the treatment areas of metabolic diseases and respiratory diseases [1] Growth Drivers - Two innovative drugs, Lai Ruitewei tablets and Angladiwei tablets, have been approved for market launch, which are expected to be significant growth drivers for the company's future performance [1]

Group 1 - The company announced a licensing agreement for the RAY1225 injection project, allowing Qilu Pharmaceutical to produce and commercialize the drug in China, while the company retains all rights outside of China [1] - The total payment for the licensing agreement is 1 billion yuan, which includes an upfront payment of 200 million yuan and milestone payments up to 800 million yuan, along with a double-digit percentage of net sales after the product launch [1] - RAY1225 is an innovative peptide drug with global intellectual property rights, showing promising results in clinical trials for weight loss, with a weight reduction of 10.1%-15.1% after 24 weeks of treatment [2] Group 2 - The company is seeing initial success in its transformation with core products like the Compound Thrombus Tong series and Brain Thrombus Tong capsules selected for national and regional procurement, indicating a strategy of "volume for price" to maintain profitability [3] - The company has a pipeline of innovative drugs, including ZSP1601 for MASH and RAY1225 for weight loss, with several Phase III clinical trials completed [3] - The company expects revenue growth from 2.53 billion yuan in 2025 to 3 billion yuan in 2027, with net profit projections of 310 million yuan in 2025 and 570 million yuan in 2026, reflecting a significant turnaround [4]

Core Viewpoint - The collaboration between Guangdong Zhongsheng Pharmaceutical Co., Ltd. and Qilu Pharmaceutical marks a significant step in the domestic innovative drug sector, with the potential to help Zhongsheng Pharmaceutical overcome challenges in its traditional business and accelerate its innovative drug development [1][2]. Group 1: Collaboration Details - Zhongsheng Ruichuang retains all rights to the licensed intellectual property and will be the marketing authorization holder after regulatory approval [2]. - The total payment under the agreement can reach 1 billion RMB, including an upfront payment of 200 million RMB and milestone payments up to 800 million RMB, along with a double-digit sales commission after the product launch [2][5]. - This agreement is seen as a crucial move for Zhongsheng Pharmaceutical to enhance its innovative drug platform and commercialize new drugs effectively [2]. Group 2: Financial Performance and Challenges - Zhongsheng Pharmaceutical's traditional business has faced significant pressure due to policies like centralized procurement, with a reported revenue decline of 5.25% in traditional Chinese medicine to 1.318 billion RMB in 2024, and a net loss of 299 million RMB [3]. - Despite a recovery in the third quarter of 2025 with a net profit of 251 million RMB, the company recognizes the need to transform into an innovative pharmaceutical enterprise to break through growth bottlenecks [3]. Group 3: Innovative Drug Development - Zhongsheng Ruichuang, established in 2018, is the core platform for innovative drug research and has successfully brought two innovative drugs to market, with seven additional projects in clinical trials [4]. - The funding from this collaboration will alleviate financial pressure on innovative drug development, supporting ongoing clinical trials for RAY1225 [5]. Group 4: Competitive Landscape - The GLP-1 drug market is becoming increasingly competitive, with both international and domestic companies intensifying their efforts [6]. - RAY1225's advantages include convenient dosing and safety, with a bi-weekly injection schedule that may enhance patient compliance, although its development progress is not leading compared to competitors [7].

Core Viewpoint - The company has received approval for a new product, which is expected to enhance its product line in the respiratory system and complement its existing innovative drugs [2]. Group 1: Company Performance - As of December 24, 2025, the stock price of Zhongsheng Pharmaceutical (002317) closed at 19.46 yuan, down 0.05%, with a turnover rate of 7.28%, trading volume of 554,100 hands, and a transaction amount of 1.08 billion yuan [1]. - On the same day, the net outflow of main funds was 2.8084 million yuan, while the net inflow of speculative funds was 21.1941 million yuan, and the net outflow of retail funds was 18.3858 million yuan [1][3]. Group 2: Product Development - The company has obtained the drug registration certificate for Ambroxol Hydrochloride Oral Solution, with approved specifications of 10ml:30mg and 100ml:0.3g, classified as a Category 4 chemical drug, equivalent to passing the consistency evaluation for generic drugs [2]. - The Ambroxol Hydrochloride Oral Solution is indicated for the treatment of viscous phlegm and difficulty in expectoration caused by acute and chronic bronchitis, and it is listed as a Class B drug under medical insurance [2]. - The projected sales for this product in Chinese public hospitals and urban retail pharmacies are 710.84 million yuan for 2022, 817.66 million yuan for 2023, and 849.53 million yuan for 2024 [2].

Core Viewpoint - The company Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales potential for the product [1][2]. Group 1: Product Information - Angladiwei Tablets are the world's first targeted drug for the PB2 subunit of the influenza A virus RNA polymerase, approved for treating adult patients with uncomplicated influenza [2]. - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a cost-effective and accessible treatment option for patients [2]. Group 2: Market Impact - The inclusion of Angladiwei Tablets in the National Medical Insurance Directory is anticipated to positively impact the company's long-term operational development and market presence [2]. - Other core products of the company, including Lai Ru Te Wei Tablets and various other formulations, continue to be listed in the National Medical Insurance Directory, supporting the company's overall product portfolio [1].

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Anladiwei Tablets (brand name: Anruiwei), in the National Medical Insurance Directory for 2025, which is expected to enhance patient access to effective treatment for influenza [1] Group 1: Product Inclusion - Anladiwei Tablets is the first global drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for the treatment of uncomplicated influenza in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a significant option for patients suffering from influenza [1] - Other core products of the company, including Lai Ru Te Wei Tablets and various formulations, continue to be included in the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of Anladiwei Tablets in the Class B category of the National Medical Insurance Directory is expected to benefit a larger patient population, offering economical, safe, and accessible medication options [1] - The drug was approved by the National Medical Products Administration in May 2025, marking a significant milestone for the company's respiratory pipeline [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations [1] Group 1: Company Developments - The company announced that its core product, Lai Ru Te Wei Tablets, along with several other products, continues to be included in the National Medical Insurance Directory [1]